KLCM Advisors’s AbbVie ABBV Stock Holding History

KLCM Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.18M	Buy	10,007 +514	+5%	+$114K	0.18%	76
2025 Q4	$2.17M	Buy	9,493 +2	+0%	+$456	0.19%	74
2025 Q3	$2.2M	Sell	9,491 -240	-2%	-$48.9K	0.22%	57
2025 Q2	$1.81M	Sell	9,731 -255	-3%	-$47.4K	0.19%	64
2025 Q1	$2.09M	Sell	9,986 -552	-5%	-$107K	0.24%	55
2024 Q4	$1.87M	Sell	10,538 -182	-2%	-$33.5K	0.22%	56
2024 Q3	$2.12M	Sell	10,720 -11,894	-53%	-$2.22M	0.25%	53
2024 Q2	$3.88M	Sell	22,614 -1,875	-8%	-$311K	0.48%	37
2024 Q1	$4.46M	Sell	24,489 -518	-2%	-$89.3K	0.57%	35
2023 Q4	$3.88M	Sell	25,007 -248	-1%	-$36.2K	0.6%	37
2023 Q3	$3.76M	Buy	25,255 +1,234	+5%	+$181K	0.71%	37
2023 Q2	$3.24M	Buy	24,021 +13,384	+126%	+$1.96M	0.63%	38
2023 Q1	$1.7M	Buy	10,637 +444	+4%	+$67.9K	0.34%	47
2022 Q4	$1.65M	Sell	10,193 -69	-0.7%	-$10.6K	0.33%	47
2022 Q3	$1.38M	Buy	10,262 +1,110	+12%	+$159K	0.32%	48
2022 Q2	$1.4M	Buy	9,152 +1,813	+25%	+$277K	0.31%	46
2022 Q1	$1.19M	Hold	7,339	–	–	0.25%	47
2021 Q4	$994K	Sell	7,339 -1,020	-12%	-$120K	0.22%	52
2021 Q3	$902K	Sell	8,359 -379	-4%	-$43.3K	0.19%	55
2021 Q2	$984K	Sell	8,738 -957	-10%	-$108K	0.22%	48
2021 Q1	$1.05M	Buy	9,695 +200	+2%	+$21.4K	0.24%	49
2020 Q4	$1.02M	Sell	9,495 -30	-0.3%	-$2.88K	0.25%	47
2020 Q3	$834K	Buy	9,525 +35	+0.4%	+$3.29K	0.24%	52
2020 Q2	$932K	Hold	9,490	–	–	0.27%	48
2020 Q1	$723K	Buy	9,490 +35	+0.4%	+$2.98K	0.23%	51
2019 Q4	$837K	Sell	9,455 -850	-8%	-$70.6K	0.19%	48
2019 Q3	$780K	Buy	10,305 +250	+2%	+$17.1K	0.2%	48
2019 Q2	$731K	Buy	10,055 +45	+0.4%	+$3.54K	0.18%	50
2019 Q1	$807K	Buy	10,010 +1,016	+11%	+$83.1K	0.2%	49
2018 Q4	$829K	Sell	8,994 -450	-5%	-$39.6K	0.24%	45
2018 Q3	$893K	Sell	9,444 -3	-0%	-$284	0.22%	44
2018 Q2	$875K	Buy	9,447 +778	+9%	+$76K	0.23%	42
2018 Q1	$821K	Sell	8,669 -2,581	-23%	-$284K	0.22%	41
2017 Q4	$1.09M	Sell	11,250 -1,500	-12%	-$141K	0.27%	38
2017 Q3	$1.13M	Sell	12,750 -800	-6%	-$60.9K	0.3%	35
2017 Q2	$983K	Buy	13,550 +9,706	+252%	+$653K	0.27%	36
2017 Q1	$250K	Sell	3,844 -250	-6%	-$15.7K	0.07%	63
2016 Q4	$256K	Sell	4,094 -1,536	-27%	-$93.8K	0.08%	66
2016 Q3	$355K	Buy	5,630 +1,048	+23%	+$67.8K	0.11%	54
2016 Q2	$284K	Buy	4,582 +300	+7%	+$18.3K	0.1%	63
2016 Q1	$245K	Buy	4,282 +250	+6%	+$13.9K	0.09%	62
2015 Q4	$239K	Buy	+4,032	New	+$232K	0.09%	60
2015 Q3	–	Sell	-4,231	Closed	-$284K	–	75
2015 Q2	$284K	Buy	4,231 +485	+13%	+$31.7K	0.07%	79
2015 Q1	$219K	Buy	3,746 +367	+11%	+$22.2K	0.06%	63
2014 Q4	$221K	Buy	+3,379	New	+$213K	0.06%	66

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KLCM Advisors's ABBV Position: Q1 2026 in Review

KLCM Advisors increased its AbbVie (ABBV) stake by 5.4% in Q1 2026, buying an estimated $114K and bringing the position to 10,007 shares worth $2.18M. The position accounts for 0.18% of the portfolio, ranked #76.

KLCM Advisors first reported a position in ABBV in Q4 2014 and has held it in 45 quarters since. The position peaked at $4.46M in Q1 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

KLCM Advisors held 10,007 shares of AbbVie worth $2.18M as of Q1 2026.
KLCM Advisors bought 514 AbbVie shares in Q1 2026, an estimated $114K.
AbbVie made up 0.18% of KLCM Advisors's portfolio in Q1 2026, its #76 holding.
KLCM Advisors first reported a position in AbbVie in Q4 2014 and has held it in 45 quarters since.
KLCM Advisors's AbbVie position peaked at $4.46M in Q1 2024.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on KLCM Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.